Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord.
1. A method of treating a mammal with amyotrophic lateral sclerosis (ALS), comprising the steps of:
injecting a recombinant adeno-associated virus (AAV) expression vector encoding hypoxia-inducible factor 1-alpha (HIF 1-alpha) into the spinal cord of a mammal with ALS, whereby life expectancy is extended; wherein the AAV comprises inverted terminal repeats of AAV-2 and an AAV-7 capsid or inverted terminal repeats of AAV-2 and an AAV-8 capsid.
2. The method of claim 1 wherein the vector is delivered into a plurality of sites in the spinal cord.
3. The method of claim 1 wherein the mammal is selected from the group consisting of a rodent, a murine, a human, and a simian.
4. The method of claim 1 wherein said mammal is a human patient.
5. A method of treating a human patient with amyotrophic lateral sclerosis (ALS), comprising the steps of: delivering to a plurality of sites in the spinal cord of a human patient with ALS a recombinant AAV vector encoding the DNA binding domain of HIF 1-alpha fused to the transcriptional activation domain of NFκB and wherein the AAV comprises inverted terminal repeats of AAV-2 and an AAV-7 capsid or inverted terminal repeats of AAV-2 and an AAV-8 capsid, whereby life expectancy is extended.
6. A method of treating a mammal with amyotrophic lateral sclerosis (ALS), comprising the steps of:
injecting a recombinant AAV expression vector encoding a DNA binding domain of HIF 1-alpha fused to a transcriptional activation domain into the spinal cord of a mammal with ALS, wherein the transcriptional activation domain is a herpes simplex virus virion protein 16 (HSV VP 16) transcriptional activation domain or a nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) transcriptional activation domain;
wherein the AAV comprises inverted terminal repeats of AAV-2 and an AAV-7 capsid or inverted terminal repeats of AAV-2 and an AAV-8 capsid.
7. The method of claim 6 wherein the vector is delivered into a plurality of sites in the spinal cord.
8. The method of claim 6 wherein the mammal is selected from the group consisting of a rodent, a murine, a human, and a simian.
9. The method of claim 6 wherein said mammal is a human patient.
10. The method of claim 6 wherein the transcriptional activation domain is a HSV VP 16 transcriptional activation domain.
11. The method of claim 6 wherein the transcriptional activation domain is an NFκB transcriptional activation domain.